ProKidney is going public in a SPAC merger that infuses the biotech with $825 million for Phase 3 tests and manufacturing of its autologous cell therapy for chronic kidney disease. More than slowing the decline in organ function, ProKidney says its cell therapy offers the potential to reverse injury caused by the condition.
Regenerative medicine might someday provide replacement organs for transplant patients. But Anthony Atala, director of the Wake Forest Institute for Regenerative Medicine, explained how the technology is already helping in the discovery and testing of drugs.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
The North Carolina organizations aim to enter a final agreement later this year, which would include plans to develop a second Wake Forest School of Medicine campus in Charlotte.
It might be unthinkable to some, but a good chunk of the provider world is still getting its feet wet with the digitization of health data. Clinical Ink, a company that was founded seven years ago out of frustration with the process of electronic data capture for clinical trials, says its business has more than […]
A biologics startup developing a way to help patients with bladder cancer by using their own cells to regenerate tissue and to reconstruct a urinary tract has expanded a Phase 1 trial to five sites and has performed the procedure on its seventh patient. But despite getting a $15 million private placement last fall, Tengion […]
Wake Forest University’s new medical school dean will come from the University of Alabama at Birmingham. Dr. Edward Abraham, chair of the department of medicine at UAB, takes his new post in Winston-Salem, North Carolina effective Aug. 1. Abraham succeeds Dr. William Applegate, who has served as dean of the Wake Forest School of Medicine […]
Share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health, healthcare navigation, and more.
Biopharmaceutical company Targacept (NASDAQ:TRGT) expects its stock offering will net $70.2 million that will fund development of a compound with targeted applications in schizophrenia and Alzheimer’s disease. Winston-Salem, North Carolina-based Targacept announced the $75 million stock offering earlier this week. On Friday, the company priced the offering at $20.50 per share. The offering is expected […]
Now that AstraZeneca (NYSE:AZN) has determined it won’t license Targacept‘s compound for schizophrenia, the drug development company is preparing to raise up to $75 million to develop the drug candidate on its own. Winston-Salem, North Carolina-based Targacept (NASDAQ:TRGT) set the dollar target in a preliminary prospectus filed Tuesday with the U.S. Securities and Exchange Commission. […]
Leukemia research at Wake Forest Baptist Medical Center has found a mutation in a protein that could open doors to a personalized medicine approach to treating the disease by limiting use in certain patients of a particularly toxic drug. The researchers at Wake Forest Baptist in Winston-Salem, North Carolina, found that a particular mutation of […]
If the compound Targacept is developing for patients with schizophrenia has a future as a commercialized drug, it will get there without drug partner AstraZeneca. AstraZeneca (NYSE:AZN) is passing up its option to license the drug compound from Winston-Salem, North Carolina drug development company Targacept (NASDAQ:TRGT). The compound, called TC-5619, showed promising results in phase […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
The Centers for Disease Control and Prevention has set a 2020 target for restaurants, bars and workplaces to be smoke free. North Carolina’s own smoking ban in restaurants and bars is a step in that direction, but that step puts it out of step with the state’s southern neighbors. The CDC notes in a new […]
Wound care startup company Medtric Biotech has developed what it says is a medical breakthrough for dressings: a bandage that both heals the wound and fights infection. Medtric says the current slate of products on the market do one or the other, but they don’t do both. Medtric could be on its way to accomplishing […]
An experimental attention deficit-hyperactivity disorder (ADHD) drug being developed by Targacept in partnership with AstraZeneca (NYSE:AZN) has failed to hit targets set for a mid-stage clinical trial. Winston-Salem, North Carolina-based Targacept, (NASDAQ:TRGT) said results from a phase 2 proof-of-concept trial for the TC-5619 showed that although patients experienced no adverse effects from the compound, the […]
It's a medical breakthrough right out of science fiction: Diseased or damaged body parts can be replaced with new tissue grown from a patient’s own cells and it's happening at Wake Forest University.
GlaxoSmithKline's decision to pull back from some neurosciences R&D led to Targacept's decision to end their partnership. The two companies in 2007 struck an agreement to develop new medicines based on Targacept's drug discovery research.